EDAP TMS (EDAP)

• Market cap: $79.3M
• 1 day: 0.47%
• 5 days: 30.06%
• 1 month: 8.16%
• 3 months: -7.83%
• 6 months: -29.10%
• Year to date: -11.67%
• 1 year: -69.89%
• 5 years: -7.02%
• 10 years: -30.26%
• Sector: Healthcare
• Industry: Medical Distribution

About: Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Employees: 310

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

136% more call options, than puts

Call options by funds: $85K | Put options by funds: $36K

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 33 [Q3] → 34 (+1) [Q4]

0.73% less ownership

Funds ownership: 42.04% [Q3] → 41.31% (-0.73%) [Q4]

15% less capital invested

Capital invested by funds: $39.8M [Q3] → $33.9M (-$5.9M) [Q4]

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2 6% downside
• Avg. target: $8.50 301% upside
• High target: $19 796% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Jefferies Michael Sarcone 0% 1-year accuracy 0 / 1 met price target	6% downside $2	Hold Downgraded	4 Apr 2025
Piper Sandler Jason Bednar 32% 1-year accuracy 12 / 38 met price target	112% upside $4.50	Overweight Maintained	28 Mar 2025
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 57 / 192 met price target	796% upside $19	Buy Reiterated	28 Mar 2025